Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23396341 | 0.98 | KDM5A (0.33) | CHRM2KDM5AKDM4C | |
| SCHEMBL15510946 | 0.91 | KDM5A (0.31) | KDM5AKDM4C | |
| SCHEMBL12788331 | 0.82 | CHRNB2 (0.35) | — | |
| SCHEMBL23396339 | 0.81 | ALDH1A1 (0.43) | CHRM2 | |
| SCHEMBL19225803 | 0.80 | ALDH1A1 (0.52) | DNM1 | |
| SCHEMBL23396338 | 0.78 | ALDH1A1 (0.41) | — | |
| SCHEMBL13759742 | 0.78 | ALDH1A1 (0.48) | DNM1 | |
| SCHEMBL20028385 | 0.77 | HTR1D (0.36) | CHRM2KDM5AKDM4C | |
| SCHEMBL12361990 | 0.77 | ALDH1A1 (0.31) | — | |
| SCHEMBL15958687 | 0.76 | CHRM2 (0.50) | CHRM2KDM5AKDM4CDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | disclosed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | SOST, BPGM, PTH1R | CHRM2 518/4885KDM5A 1144/4885KDM4C 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.